Published in FEBS J on June 26, 2006
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol (2008) 1.25
Novel microtubule-targeting agents - the epothilones. Biologics (2008) 1.06
Recent advances in the study of the bioactive conformation of taxol. ChemMedChem (2009) 0.94
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer (2013) 0.90
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis (2013) 0.88
Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat (2011) 0.87
Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One (2011) 0.87
Drug discovery targeting cell division proteins, microtubules and FtsZ. Bioorg Med Chem (2014) 0.86
Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther (2009) 0.85
Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br J Cancer (2013) 0.85
Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg Med Chem Lett (2009) 0.81
The bat flower: a source of microtubule-destabilizing and -stabilizing compounds with synergistic antiproliferative actions. J Nat Prod (2013) 0.81
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) (2014) 0.80
A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells. PLoS One (2013) 0.78
Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis. BMC Res Notes (2012) 0.78
Epothilones: From discovery to clinical trials. Curr Top Med Chem (2014) 0.77
A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell (2011) 9.24
The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A (2007) 3.93
Critical assessment of methods of protein structure prediction (CASP)--round x. Proteins (2013) 3.78
Critical assessment of methods of protein structure prediction-Round VII. Proteins (2007) 3.23
Evaluation of annotation strategies using an entire genome sequence. Bioinformatics (2003) 2.66
Critical assessment of methods of protein structure prediction (CASP)--round 6. Proteins (2005) 2.58
Critical assessment of methods of protein structure prediction - Round VIII. Proteins (2009) 2.25
Assessment of predictions in the model quality assessment category. Proteins (2007) 2.25
Protein function annotation by homology-based inference. Genome Biol (2009) 2.20
Critical assessment of methods of protein structure prediction (CASP)--round IX. Proteins (2011) 2.08
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
The PMDB Protein Model Database. Nucleic Acids Res (2006) 1.94
Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol (2009) 1.93
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Ten simple rules for developing a short bioinformatics training course. PLoS Comput Biol (2011) 1.84
Assessment of the assessment: evaluation of the model quality estimates in CASP10. Proteins (2013) 1.60
PIGS: automatic prediction of antibody structures. Bioinformatics (2008) 1.59
Evaluating the usefulness of protein structure models for molecular replacement. Bioinformatics (2005) 1.58
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother (2011) 1.51
Evolution of bacterial and archaeal multicomponent monooxygenases. J Mol Evol (2003) 1.46
Evaluation of disorder predictions in CASP9. Proteins (2011) 1.46
Evaluation of CASP8 model quality predictions. Proteins (2009) 1.44
Evaluation of model quality predictions in CASP9. Proteins (2011) 1.43
Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorg Med Chem Lett (2002) 1.29
Evaluation of residue-residue contact predictions in CASP9. Proteins (2011) 1.26
Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem (2007) 1.26
Assessment of protein disorder region predictions in CASP10. Proteins (2013) 1.25
FunClust: a web server for the identification of structural motifs in a set of non-homologous protein structures. BMC Bioinformatics (2008) 1.23
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica (2010) 1.17
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
Relationship between multiple sequence alignments and quality of protein comparative models. Proteins (2005) 1.16
N-myristoylation determines dual targeting of mammalian NADH-cytochrome b5 reductase to ER and mitochondrial outer membranes by a mechanism of kinetic partitioning. J Cell Biol (2005) 1.14
Involvement of polyamine oxidase in wound healing. Plant Physiol (2007) 1.11
Automatic procedure for using models of proteins in molecular replacement. Proteins (2007) 1.11
Evaluation of residue-residue contact prediction in CASP10. Proteins (2013) 1.10
Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives. J Med Chem (2007) 1.09
The prediction of protein function at CASP6. Proteins (2005) 1.08
Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem (2009) 1.07
Structural repertoire of immunoglobulin λ light chains. Proteins (2011) 1.07
Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci (2008) 1.06
The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J (2011) 1.05
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem (2006) 1.05
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother (2010) 1.04
Mg2+ binding and archaeosine modification stabilize the G15 C48 Levitt base pair in tRNAs. RNA (2007) 1.03
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem (2008) 1.03
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr (2010) 1.03
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs (2010) 1.02
Guanylated diamines, triamines, and polyamines: chemistry and biological properties. Chem Rev (2011) 1.01
A database of immunoglobulins with integrated tools: DIGIT. Nucleic Acids Res (2011) 1.01
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J Med Chem (2011) 1.00
FIDEA: a server for the functional interpretation of differential expression analysis. Nucleic Acids Res (2013) 0.98
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. Bioorg Med Chem Lett (2012) 0.98
Accurate energies of hydrogen bonded nucleic acid base pairs and triplets in tRNA tertiary interactions. Nucleic Acids Res (2006) 0.97
Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. Eur J Med Chem (2010) 0.97
Lennard-Jones potential and dummy atom settings to overcome the AUTODOCK limitation in treating flexible ring systems. J Chem Inf Model (2007) 0.97
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies. J Med Chem (2002) 0.96
Exploring the cytochrome c folding mechanism: cytochrome c552 from thermus thermophilus folds through an on-pathway intermediate. J Biol Chem (2003) 0.96
Prediction of site-specific interactions in antibody-antigen complexes: the proABC method and server. Bioinformatics (2013) 0.96
An automatic method for identifying surface proteins in bacteria: SLEP. BMC Bioinformatics (2010) 0.96
Protein kinases: docking and homology modeling reliability. J Chem Inf Model (2010) 0.95
Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. J Med Chem (2006) 0.95
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem (2007) 0.95
Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors. J Med Chem (2005) 0.95
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One (2013) 0.94
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett (2010) 0.94
Flavin-containing polyamine oxidase is a hydrogen peroxide source in the oxidative response to the protein phosphatase inhibitor cantharidin in Zea mays L. J Exp Bot (2006) 0.94
Classification of proteins based on the properties of the ligand-binding site: the case of adenine-binding proteins. Proteins (2002) 0.94
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem (2008) 0.93
Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen (2012) 0.93
Phospho3D 2.0: an enhanced database of three-dimensional structures of phosphorylation sites. Nucleic Acids Res (2010) 0.93
Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett (2004) 0.93
Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr Med Chem (2006) 0.92
Inhibition of polyamine and spermine oxidases by polyamine analogues. FEBS J (2006) 0.92
Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures. Org Biomol Chem (2012) 0.92
A model of the complex between the PfEMP1 malaria protein and the human ICAM-1 receptor. Proteins (2007) 0.92
Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem (2004) 0.92
Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease. J Clin Invest (2013) 0.91
Ten years of predictions ... and counting. FEBS J (2005) 0.91
Raft component GD3 associates with tubulin following CD95/Fas ligation. FASEB J (2009) 0.91
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis (2008) 0.91
Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis. Bioorg Med Chem (2008) 0.90
Massive screening of copy number population-scale variation in Bos taurus genome. BMC Genomics (2013) 0.90
GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. Bioinformatics (2006) 0.89
MODexplorer: an integrated tool for exploring protein sequence, structure and function relationships. Bioinformatics (2013) 0.89
Engineering stable cytoplasmic intrabodies with designed specificity. J Mol Biol (2003) 0.89
Improving your target-template alignment with MODalign. Bioinformatics (2012) 0.89
Molecular basis for the binding of competitive inhibitors of maize polyamine oxidase. Biochemistry (2004) 0.89
Synthesis, biological evaluation, and molecular modeling of oleuropein and its semisynthetic derivatives as cyclooxygenase inhibitors. J Agric Food Chem (2009) 0.89